Comprehensive analysis of metformin-associated lactic acidosis: Insights from the FDA Adverse Event Reporting System (FAERS)
Abstract
The present study aims to evaluate metformin-associated lactic acidosis (MALA) using real-world data from the Food and Drug Administration Adverse Event Reporting System (FAERS), providing reference for rational metformin use in clinical practice. Relevant adverse event data from January 2018 to March 2024 was extracted from the FAERS database. Disproportionality analysis, logistic regression, and time-to-event analysis were performed to assess risk factors, temporal patterns, and potential drug interactions associated with MALA. Among 40,883 metformin-related adverse event reports, 10,370 were MALA cases. Diabetes (adjusted odds ratio [OR]: 2.35, 95% confidence interval [CI]: 2.03-2.74), heart disease (adjusted OR: 1.75, 95% CI: 1.44-2.14), and hypertension (adjusted OR: 1.40, 95% CI: 1.21-1.62) were identified as significant risk factors. Contrast media showed the highest signal strength for drug interactions (reporting odds ratio = 323.7, 95% CI: 226.8-461.99), followed by furosemide and bisoprolol. The median time to lactic acidosis onset was 106 days, significantly longer than the 20 days for other adverse events (P < .0001), with 44.0% occurring within 30 days and 40.4% after 360 days of therapy initiation. Taken together, our comprehensive analysis of the FAERS database enhances understanding of MALA risk factors and temporal patterns, contributing to informed decision-making in metformin's clinical application and facilitating timely management of this potentially…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.